Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedSite revision indicator updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedUpdated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision: v3.4.2 was added. The funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check63 days agoChange DetectedA government funding lapse notice is now displayed on the page, and the site revision tag has been updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange DetectedGlossary visibility was added and QC-related labels were updated to show the new revision (v3.4.0), replacing the previous version and capitalization variants.SummaryDifference0.2%

- Check84 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 on the page; no substantive changes to study details or eligibility criteria are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.